1. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
2. Fisher B, Anderson S, Wolmark N, et al: Chemotherapy with and without tamoxifen for patients with ER negative breast cancer and negative nodes: Results from NSABP B23. Proc Am Soc Clin Oncol 19: 72,2000 (abstr 277)
3. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
4. Mourisden H, Andersen J, Andersson M, et al: Adjuvant anthracycline in breast cancer: Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc Am Soc Clin Oncol 18: 68,1999 (abstr 254)
5. Hutchins L, Green S, Ravdin P, et al: CMF versus CAF with and without tamoxifen in high risk node negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of Intergroup trial INT 0102. Proc Am Soc Clin Oncol 17: 1,1998 (abstr 1)